 |
API Development: Risk Evaluation and Control of Genotoxic Impurities |
Event Date: November 08, 2012 at 10:00 AM EST |
Developing a successful synthesis and manufacturing process for a small-molecule active pharmaceutical ingredient (API) requires not only approaches to optimize product yield, purity, and process conditions, but also a full understanding of the regulatory issues to ensure product quality. When developing synthetic routes to APIs, the stages at which impurity generation occurs must be elucidated to identify and determine impurities, including genotoxic impurities, in order in control their formation during a synthesis. This 60-minute webcast will offer insight from leading industry experts on current regulatory guidelines, including an analysis of FDA’s recently issued guidance in June 2012 on genotoxic impurities, and the analytical and chemical approaches used to control and mitigate the risk of genotoxic impurities in small-molecule API development. The webcast will offer insight on:
- Regulatory guidelines regarding genotoxic impurities
- Analytical and chemical approaches
- Risks of genotoxic impurities in small-molecule API development
|
Moderator:
Patricia Van Arnum
Executive Editor
Pharmaceutical Technology
Speakers:
Ponnaiah Ravi, PhD
Senior Vice-President of R&D
Neuland Laboratories Limited
Christopher M Cimarusti, PhD
Non-Executive Director
Neuland Laboratories Limited
Bo Shen, PhD
Principal Scientist, Analytical R&D Department, Amgen
Chair of the AAPS Pharmaceutical Trace Impurities Focus Group
Edward Delaney, PhD
President
Reaction Science Consulting
|
IMPORTANT - PLEASE READ
This is a FREE streaming audio Webcast and does not require a phone line. If you have any questions regarding this Webcast, please contact Sara Barschdorf, sbarschdorf@advanstar.com.
Register for this FREE Webcast!
|
 |
|